bioProcessUK spotlight: Astrea Bioseparations

Daniella Steel Astrea Bio.png

In the lead up to the 20th annual bioProcessUK conference, ‘New frontiers in bioprocessing in the next two decades’, on 28 – 30 November 2023 in Brighton, Daniella Steel, Senior Manager, Product Strategy at Astrea Bioseparations, discusses efficient downstream processing of viral vectors, extracellular vesicles, and nucleic acid targets with next-generation nanofiber technology.

The need for a bioprocessing revolution

Bioprocessing is the cornerstone of many therapeutic advancements, particularly in the field of cell and gene therapy. Over the years, this domain has witnessed significant progress, yet challenges remain. Legacy solutions have reigned for many years, and the purification of large modalities are currently utilizing methods that are not fit for purpose.

Bioprocessing has long relied on these tried-and-true methods, but the demand for more efficient solutions has spurred Astrea Bioseparations to challenge convention, determined to create a solution that preserves viral vector yield to maximize efficiency.

As the sector navigates the next two decades, embracing novel technologies and fostering collaborative approaches will prove pivotal. The pace of evolution in the bioprocessing landscape is extraordinary, and by confronting challenges head-on, bolstering regulatory cooperation, and embracing ground-breaking innovations, the industry stands on the cusp of a new therapeutic epoch – one that promises to enrich patients' lives on a global scale.

Untitled design.png 1

The bridge between precision and efficiency

The bioprocessing industry finds itself divided between viral vectors and synthetic encapsulation methods for drug delivery. While the latter lacks specificity, viral vectors grapple with purification challenges.

If we can bridge the ambition of precision therapy with the reality of efficient bioprocessing, there is the potential to unlock effective viral vector-based therapies, more cost effectively than ever before and is poised to revolutionize the medical landscape.

Astrea Bioseparations has developed a cutting-edge nanofiber-based bioprocessing innovation, AstreAdept®, to reform the purification of biological feed streams. The inherent properties of nanofibers bring unique capabilities that can redefine the bioprocessing of large cell and gene therapy modalities, such as viral vector, pDNA and extracellular vesicles by supercharging th purification processes.

Technology architecture

Featuring novel composite electrospun nanofiber adsorbent with an expansive flowpath and a vast binding surface area, the unique characteristics enable the application of chemistries for the purification of biological feed streams in ways previously unattainable. This subsequently compresses processes and presents opportunities to purify larger modalities more effectively than ever before.

This novel adsorbent is designed to be used with standard chromatography hardware, from lab-scale equipment to manufacturing-grade single-use systems, allowing rapid implementation and expanded capabilities. The potential to remove limitations in current cell & gene therapy purification processes holds promise for more efficient therapeutic development.

Unleashing the future of bioprocessing

BioprocessUK Conference

AstreAdept® technology isn't merely a technological advancement; it's a transformative force set to reshape bioprocessing as we understand it. With a visionary team steering the ship, the industry can anticipate expedited processes, heightened efficiency, and a broader horizon of possibilities in therapeutic development. The launch of three new HERO devices: ExoHERO®, pNDAHERO®, LentiHERO® in September presents a new era in bioprocessing – propelling us closer to accessible and impactful therapies that can touch lives across the globe.

About Astrea Bioseparations

Astrea Bioseparations is the only bioseparations company to offer ligand discovery and adsorbent development services in combination with large-scale manufacture of chromatography adsorbents and production of pre-packed chromatography columns to GMP standards.

Astrea offers a variety of custom affinity ligand/adsorbent development solutions, which can be designed to meet specific purification/manufacture criteria, an extensive range of off-the-shelf bioseparation products for the recovery and purification of biologicals (such as recombinant proteins, viral vectors and plasmid DNA) and removal of problem contaminants (including endotoxin, prions and serine proteases) from research to process scale (up to 1000L batch size).

Astrea also offers a range of semi-disposable and pre-packed GMP Ready disposable bioprocess columns.

Learn more about Astrea Bioseparations and meet them at the 20th Annual bioProcessUK conference.


More news and updates 

CEO Update - 8 April 2024

I don’t always start Newscast with a technical detail – but this one matters and underpins the work of many, many companies in our Association. In short, keep doing your experiments and manufacturing medicines as normal as we work hard to keep your reagents and materials supply chain operating smoothly.

How to build a high-performance life science team

In this blog, Olivia Fletcher-Hogg, Programme Manager at Pioneer Group, provides actionable insights for building high-performance teams in the life sciences and biotech sector, from fostering a positive work culture to empowering employee development.

AI in life sciences: regulating AI technologies and the product liability implications

Recent regulatory developments in the EU and UK suggest a proactive stance on governing AI technologies, with the EU introducing comprehensive regulations and the UK proposing reforms to align with emerging digital technologies.

CEO Update - 25 March 2024

I’m delighted to be opening PULSE this morning. It is a free three-day leadership and entrepreneurship training programme for up-and-coming life sciences entrepreneurs that we’ve developed and delivered with the Francis Crick Institute. Read on for the latest on EU biotech initiatives, Biosecurity Leadership Council and boost for UK cell and gene therapy.

AI in life sciences: an evolving risk landscape

In this article, Marsh’s Life Sciences industry practice leader Jenny Yu and experts from Kennedys take a look at the topic of AI in the life sciences sector, the associated risks regulation and potential liability issues, as well as how companies can seek to ‘future-proof’ themselves in the face of rapid change.

CEO Update - 18 March 2024

A year ago, the life sciences sector faced a significant challenge with the SVB UK collapse. This event threatened to disrupt vital research and development for many companies. Today, we're taking a moment to reflect on that experience and share valuable resources to help us all build a more resilient future. 

Member spotlight: Meet OMass Therapeutics

In this blog, Ros Deegan, CEO of OMass Therapeutics, a member of the BIA Board and a member of the Prime Ministers 2024 Business Council, shares how the company is pioneering new approaches to drug discovery, targeting challenging diseases with their advanced platform.

CEO Update - 11 March 2024

The Chancellor's Budget last week had plenty for UK life sciences. The BIA’s mission to unlock pension funds for investment into UK life sciences took a great leap forward with the announcement that the life sciences team of Intermediate Capital Group (ICG) has successfully partnered with Phoenix Group.

Breaking Barriers: Leigh Stoddart reflects on #IWD2024

Dr. Leigh Stoddart, Principal Scientist at Excellerate Bioscience and newly announced Fellow for the British Pharmacological Society (BPS), reflects on her career journey on International Women’s Day 2024. From her undergrad days at Unilever to her current role, Leigh's passion for receptor pharmacology shines. She discusses her role at Excellerate, the significance of her BPS fellowship, and the importance of International Women's Day in science.

IRC unveils comprehensive analysis of the UK's deep biotech infrastructure landscape

In this blog, Maddie Cass, Senior Policy and Public Affairs Executive at the BIA, shares insights on the Innovation & Research Caucus (IRC) recent report, which examines the current state of the UK's non-health engineering biology infrastructure.


More within